NCT01466062View on ClinicalTrials.gov

Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions

PHASE3CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Respiratory Syncytial Virus Infection
Interventions
DRUG

Palivizumab

Trial Locations (6)

Unknown

Site Reference ID/Investigator# 56847, Hyōgo

Site Reference ID/Investigator# 56845, Shimotsuke

Site Reference ID/Investigator# 56842, Tokyo

Site Reference ID/Investigator# 56844, Tokyo

Site Reference ID/Investigator# 56846, Tokyo

Site Reference ID/Investigator# 56843, Yokohama

All Listed Sponsors
lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01466062 - Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions | Biotech Hunter | Biotech Hunter